# Effects of Probiotics on the Patients With End Stage Renal Disease (ESRD)

Study · id `cardio:ct-nct03010735` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03010735](<https://clinicaltrials.gov/study/NCT03010735>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03010735

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 150 participants.

## Technical summary

Registry record NCT03010735. Randomized; quadruple masking; primary purpose prevention. Start 2015-06 (registry gives no type); primary completion 2017-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 2/3
- Enrolled: 150 participants (enrolled count; ClinicalTrials.gov record NCT03010735, source copy `cardio:ctgov-nct03010735-2020-10-22`, retrieved 2026-10-26)
- Start date: 2015-06 (registry gives no type) (ClinicalTrials.gov record NCT03010735, source copy `cardio:ctgov-nct03010735-2020-10-22`, retrieved 2026-10-26)
- Primary completion: 2017-02 (actual) (ClinicalTrials.gov record NCT03010735, source copy `cardio:ctgov-nct03010735-2020-10-22`, retrieved 2026-10-26)
- Completion: 2017-12 (actual) (ClinicalTrials.gov record NCT03010735, source copy `cardio:ctgov-nct03010735-2020-10-22`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03010735, source copy `cardio:ctgov-nct03010735-2020-10-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03010735-2020-10-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effects of Probiotics on the Patients With End Stage Renal Disease (ESRD)
- Condition: Kidney Failure, Chronic
- Intervention (Dietary supplement): probiotics
- Intervention (Dietary supplement): Placebo
- Lead sponsor: China Agricultural University
- Lead sponsor class: OTHER
- Collaborator: Peking University Aerospace Center Hospital
- Collaborator class: OTHER
- Collaborator: General Hospital of Chinese Armed Police Forces
- Collaborator class: OTHER
- Collaborator: Beijing Anzhen Hospital
- Collaborator class: OTHER
- Collaborator: Beijing Biostats Technology Co. Ltd.
- Collaborator class: UNKNOWN
- Collaborator: Beijing Heyiyuan Biotech Co. Ltd.
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as a collaborator: General Hospital of Chinese Armed Police Forces (`cardio:org-general-hospital-of-chinese-armed-police-forces`)
- Registry lists this organization as a collaborator: Beijing Anzhen Hospital (`cardio:org-beijing-anzhen-hospital`)

## Provenance

Content hash: 8f23d22cfa6b1fdc2a1164e3f5b28b894ce6e56266cbd9565e77781306e79c1a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
